Iovance Biotherapeutics
IOVA
50 hedge funds and large institutions have $313M invested in Iovance Biotherapeutics in 2015 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$30.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$24.2M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$14.9M |
| 5 |
QF
QVT Financial
New York
|
+$14.9M |
Top Sellers
IOVA Hedge Fund Activity: Q1 2015 in Review
50 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2015, worth a combined $313M.
Buyers outnumbered sellers: 50 funds opened new IOVA positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $64.7M.
- 50 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $313M of Iovance Biotherapeutics stock for Q1 2015.
- 50 funds opened new Iovance Biotherapeutics positions in Q1 2015 and 0 closed out, a net change of +50 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2015 was Fidelity Investments, an estimated $64.7M added.
Based on aggregated 13F filings for Q1 2015.